Buradasınız

Anasayfa » Content

Tip 2 Diabetes Mellituslu Hastalarda Mikroalbuminüri, İnsülin Direnci ve Kardiyovasküler Risk

Microalbuminuria, Insulin Resistance and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2006

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Recent studies focus on the relationship between target organ damage and cardiovascular disease risk with microalbuminuria (MAU) in type 2 diabetes. In this study, the relation between MAU and glycemic control with insulin resistance (IR) and other cardiovascular risk factors in patients with type 2 diabetes mellitus (DM) was evaluated. 29 microalbuminuric and 68 normoalbuminuric type 2 DM patients with normal renal function and no insulin requirement were included in the study. In all patients, anthropometric measurements and blood pressures were recorded. Serum fasting and postprandial glucose, insulin, CRP, transferrin, fibrinogen levels, lipid profiles and renal functions were measured. IR was calculated with Homeostasis Model Assessment (HOMA) method. Blood pressures, serum insulin and HOMA-IR (8.64 ± 6.9 vs. 5.42 ± 5.4) values in patients with MAU were higher than those of normoalbuminuric ones, while HDLcholesterol levels of patients with MAU were lower (45.3 ± 7.8 mg/dl vs. 49.8 ± 7.5 mg/dl). When HbA1C values were taken into account, glycemic controls of 18 patients (62%) in MAU group and 26 (38.8%) in normoalbuminuria group were poor. The ratios of overweight, obese, hypertensive and dyslipidemic patients and frequencies of retinopathy or neuropathy were similar in both groups. MAU was correlated with waist circumference, waist-to-hip ratio, VLDL-cholesterol and triglyceride levels. Logistic regression analysis showed that female gender, smoking and HOMA-IR value >5.51 were risk factors for MAU. Finally, IR increased in type 2 diabetic patients with MAU. Treatment approaches reducing IR will be useful in these patients.
Bookmark/Search this post with
Abstract (Original Language): 
Son çalışmalar tip 2 diyabette mikroalbuminüri (MAU) varlığı ile hedef organ hasarları ve kardiyovasküler hastalık riski arasındaki ilişkilere yönelmişlerdir. Bu çalışmada, Tip 2 diabetes mellituslu (DM) hastalarda MAU ile glisemik kontrol, insülin direnci (İR) ve diğer kardiyovasküler risk faktörleri arasındaki ilişki değerlendirilmiştir. İnsülin gereksinimi olmayan, normal renal fonksiyonlu 29 mikroalbuminürik ve 68 normoalbuminürik tip 2 DM’lu hasta çalışmaya dahil edildi. Tüm hastalarda antropometrik ölçümler ve kan basıncı kaydedildi. Serum açlık ve tokluk kan şekerleri, insülin, CRP, transferrin, fibrinojen düzeyleri, lipid profili ve renal fonksiyonlar ölçüldü. İR, Homeostasis Model Assessment (HOMA) metodu ile hesaplandı. HDL-kolesterol düzeyleri MAU’li hastalarda daha düşük (45.3 ± 7.8 mg/dl’ye karşılık 49.8 ± 7.5 mg/dl) iken, kan basınçları, serum insülin ve HOMA-İR (8.64 ± 6.9 karşılık 5.42 ± 5.4) değerleri MAU’li hastalarda normoalbuminüriklerden daha yüksekti. HbA1C değerleri dikkate alındığında MAU gurubunda 18 (%62), normoalbuminüri gurubunda 26 (%38.8) hastanın glisemik kontrolü kötü idi. Kilolu, obez, hipertansif, dislipidemik hasta, retinopati veya nöropati sıklığı oranları her iki gurupta benzerdi. MAU bel çevresi, bel kalça oranı, VLDL-kolesterol ve trigliserid düzeyleri ile koreleydi. Lojistik regresyon analizi MAU için kadın cinsiyet, sigara kullanımı ve HOMA-IR değerinin >5.51 olmasının bir risk faktörü olduğunu gösterdi. Sonuçta İR MAU’li tip 2 diyabetli hastalarda artmıştır. İR’ni azaltan tedavi yaklaşımları bu hastalarda yararlı olacaktır.
FULL TEXT (PDF): 
PDF icon arastirmax-tip-2-diabetes-mellituslu-hastalarda-mikroalbuminuri-insulin-direnci-kardiyovaskuler-risk.pdf
  • 2
35-41
  • Turkish

REFERENCES

References: 

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden
of diabetes and its complications: estimates and projections to
the year 2010. Diabet Med 1997;14(Suppl 5):S1-85.
2. King H, Aubert RE, Herman WH. Global burden of diabetes,
1995-2025: prevalence, numerical estimates, and projections.
Diabetes Care 1998;21:1414-31.
3. Bakris GL. Pathogenesis of hypertension in diabetes. Diabetes
Reviews 1995;3:460-76.
4. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted
syndrome responsible for NIDDM, obesity, hypertension,
dyslipidemia, and atherosclerotic cardiovascular disease.
Diabetes Care 1991;14:173-93.
5. Weichenhain B, van Kooten H-J, Standl E. Hypertension and
insulin resistance. Glycaemia and insulinaemia in overweight
hypertensive patients. Drugs 1993; 46(Suppl.2):183-8.
6. Reaven GM. Role of insulin resistance in human disease.
Diabetes 1988;37:1595-607.
7. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of
NIDDM: A balanced overview. Diabetes Care 1992;15:318-68.
8. Donnelly R, Yeung JM, Manning G. Microalbuminuria: a
common, independent cardiovascular risk factor, especially
but not exclusively in type 2 diabetes. J Hypertens
2003;21(Suppl 1):S7-12.
9. Verdecchia P, Reboldi GP. Hypertension and
microalbuminuria: the new detrimental duo. Blood Press
2004;13:198-211.
10. Jager A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM,
Stehouwer CD. Microalbuminuria is strongly associated with
NIDDM and hypertension, but not with the insulin resistance
syndrome: the Hoorn Study. Diabetologia 1998;41:694-700.
11. Rizvi A, Varasteh B, Chen YD, Reaven GM. Lack of a
relationship between urinary albumin excretion rate and
insulin resistance in patients with non-insulin-dependent
diabetes mellitus. Metabolism 1996;45:1062-4.
12. Emoto M, Nishizawa Y, Maekawa K, et al. Insulin resistance
in non-obese, non-insulin-dependent diabetic patients with
diabetic nephropathy. Metabolism 1997;46:1013-8.
13. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC,
Gabriel M, Haffner SM. Microalbuminuria is associated with
insulin resistance in nondiabetic subjects: the insulin
resistance atherosclerosis study. Diabetes 1998;47:793-800.
14. Chan JC, Tomlinson B, Nicholls MG, Swaminathan R,
Cheung CK, Woo J, Cockram CS. Albuminuria, insulin
resistance and dyslipidaemia in Chinese patients with noninsulin-dependent diabetes (NIDDM). Diabet Med
1996;13:150-5.
15. Pinkney JH, Denver AE, Mohamed-Ali V, Foster C, Yudkin
JS. Insulin resistance in non-insulin-dependent diabetes
mellitus is associated with microalbuminuria independently of
ambulatory blood pressure. J Diabetes Complications
1995;9:230-3.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the
concentration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge. Clin Chem
1972;18:499-502.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor DA, Treacher
DF, Turner RC. Homeostasis model assessment: insülin
resistance and β-cell function from fasting plasma glucose and
insulin concentrations in man. Diabetologia 1985;28:412-9.
18. NHLBI. Clinical Guidelines on the identification, evaluation,
and treatment of overweight and obesity in adults: The
evidence report. National Institutes of Health. Obes Res
1998;6(Suppl 2):S51-209.
19. Boccara F, Cohen A. Interplay of diabetes and coronary heart
disease on cardiovascular mortality. Heart 2004;90:1371-3.
20. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension,
and cardiovascular disease: an update. Hypertension. 2001
Apr;37(4):1053-9.
21. Goligorsky MS, Chen J, Brodsky S. Workshop: endothelial
cell dysfunction leading to diabetic nephropathy: focus on
nitric oxide. Hypertension 2001;37(2 Part 2):744-8.
22. Lane JT. Microalbuminuria as a marker of cardiovascular and
renal risk in type 2 diabetes mellitus: a temporal perspective.
Am J Physiol Renal Physiol 2004;286:F442-50.
23. Gerstein HC, Mann JF, Yi Q, et al.; HOPE Study
Investigators. Albuminuria and risk of cardiovascular events,
death, and heart failure in diabetic and nondiabetic
individuals. JAMA 2001;286:421-6.
24. Takahashi N, Anan F, Nakagawa M, et al. Microalbuminuria,
cardiovascular autonomic dysfunction, and insulin resistance
in patients with type 2 diabetes mellitus. Metabolism
2004;53:1359-64.
25. Yu Y, Suo L, Yu H, Wang C, Tang H. Insulin resistance and
endothelial dysfunction in type 2 diabetes patients with or
without microalbuminuria. Diabetes Res Clin Pract
2004;65:95-104.
26. Kim YI, Kim CH, Choi CS, et al. Microalbuminuria is
associated with the insulin resistance syndrome independent
of hypertension and type 2 diabetes in the Korean population.
Diabetes Res Clin Pract 2001;52:145-52.
27. Deyneli O, Ersoz HO, Gogas-Yavuz D, Fak AS, Akalin S.
The association between autonomic neuropathy, and
microalbuminuria with altered diurnal blood pressure
variation in type 2 diabetic patients. Turkish Journal of
Endocrinology and Metabolism 2000;1:19-25.
28. Cakir M, Baskal N, Güllü S, et al. Microalbuminuria,
nondipping and diastolic dysfunction in normotensive type 2
diabetic patients. Turkish Journal of Endocrinology and
Metabolism 2003;1:23-29.
29. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR,
Groop L. The metabolic syndrome influences the risk of
chronic complications in patients with type II diabetes.
Diabetologia 2001;44:1148-54.
30. Zander E, Heinke P, Gottschling D, et al. Increased prevalence
of elevated urinary albumin excretion rate in type 2 diabetic Diabetes Mellitusta Mikroalbuminüri, İnsülin Direnci ve Kardiyovasküler Risk
41
patients suffering from ischemic foot lesions. Exp Clin
Endocrinol Diabetes 1997;105(Suppl 2):51-3.
31. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP,
Haffner SM. Inflammation and microalbuminuria in
nondiabetic and type 2 diabetic subjects: The Insulin
Resistance Atherosclerosis Study. Kidney Int 2000;58:1703-
10.
32. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC,
Speizer FE, Nathan DM, Manson JE. The impact of diabetes
mellitus on mortality from all causes and coronary heart
disease in women: 20 years of follow-up. Arch Intern Med
2001;161:1717-23.
33. Becker A, Bos G, de Vegt F, et al. Cardiovascular events in
type 2 diabetes: comparison with nondiabetic individuals
without and with prior cardiovascular disease. 10-year followup of the Hoorn Study. Eur Heart J 2003;24:1406-13.

Thank you for copying data from http://www.arastirmax.com